Recombinant protein production is a multibillion-dollar market. Among several expression systems, yeast cell factories combine the advantages of being single cells, such as fast growth and easy genetic manipulation, as well as eukaryotic features including a secretory pathway leading to correct protein processing and post-translational modifications. In this respect, especially the engineering of yeast glycosylation to produce glycoproteins of human-like glycan structures is of great interest.
Figure 1. Expression of human proteins in yeast can lead to an arrest in cell growth and division, and this can be used as a basis for drug screens. (Julian A. Simon & Antonio Bedalov, 2004)
Please see Creative Biostructure’s cell-free and cell-based expression services.